ArticlePLoS computational biology2026
Application of machine learning with MALDI-TOF MS for rapid differentiation between methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApplication of machine learning with matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry may allow rapid differentiation between methicillin-susceptible (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) and enable earlier AST-guided antibiotic use, but prior studies saw limited model performance. This study aims to apply novel machine learning techniques to a large dataset to create a prediction model with potential for clinical applications.
methodsThis study has employed one of the largest datasets to date. 24487 Staphylococcus aureus isolates (13776 MRSA and 10711 MSSA) were collected between Jan 2021 and May 2024 in Hong Kong. These spectra were randomly divided into an 80:20 training-validation split to develop models of various structures. Top models, including a large-scale neural network (NN), the LightGBM gradient boosting framework (LGBM), and the weight-averaging ensemble model ("ensemble") of NN and LGBM, underwent prospective testing using 2975 additional clinical isolates (1867 MRSA and 1108 MSSA), and external validation using 1000 spectra (500 MRSA and 500 MSSA) from Taiwan.
resultsThe NN, LGBM, and ensemble models all achieved high performance with accuracy of 0.9284-0.9388 and AUPRC of 0.9843-0.9866 during prospective testing. The models are well-calibrated and confidence thresholds increased the accuracy to 0.9697-0.9777 by rejecting 20% of low-confidence predictions. External validation revealed accuracy of 0.695-0.723 and AUPRC of 0.8409-0.8765 with an increased number of false negatives. Shapley additive explanations revealed top feature groups consistent with previous studies, but feature importance was found to be geographically specific.
conclusionsWe present new machine learning models with high performance in differentiating between MRSA and MSSA. Model performance can be further boosted with confidence thresholds, but models are not generalizable across different geographical areas. Clinical applications should use geographically specific models with fallback to traditional AST methods for low confidence predictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.